Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FT-002 subretinal gene therapy in X-linked retinitis pigmentosa (RPGR mutations)
CTR20240458Phase 2Active
- Sponsor
- Frontera Therapeutics
- Start
- Feb 2024
- Modality
- Recombinant Proteins and Enzymes, Viral Vectors → Gene Addition/Replacement → Gene Therapies
- Countries
- 1
01
Overview
A Phase 2 trial of FT-002 in retinitis pigmentosa (RP), sponsored by Frontera Therapeutics. Started Feb 2024; status: active.
02
Drugs
FT-002
03
Conditions
retinitis pigmentosa (RP)
Beyond the preview
Go deeper on CTR20240458.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20240458.